


MIT OpenCourseWare  
<http://ocw.mit.edu>

HST.939 Designing and Sustaining Technology Innovation for Global Health Practice  
Spring 2008

For information about citing these materials or our Terms of Use, visit: <http://ocw.mit.edu/terms>.



# **Everything You Ever Wanted to Know About Medical Device Marketing Clearance**

**Robert Phillips, Ph.D.**

**Chief, Radiological Devices Branch**

***Office of Device Evaluation***

***Center for Devices and Radiological Health***

***FDA***

***RAP@cdrh.fda.gov***

# Outline

- **Sources of Information**
- **Statutory Basis**
- **Routes to Market (Clearance Processes)**
- **Investigational Use**
- **Submission Fees**

# Contacts

- Web site: [WWW.FDA.GOV/CDRH](http://WWW.FDA.GOV/CDRH)
- Division of Small Manufacturers  
Assistance: 1-800-638-2041
- Program Operations Staff; IDE, 510(k),  
PMA: (301) 594-1190
- Radiology Branch: (301) 594-1212
- For *Post-market reporting*:  
MedWatch: 1-800-FDA-1088



# U.S. Food and Drug Administration



## CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

[FDA Home Page](#) | [Search](#) | [CDRH A-Z Index](#) | [Contact CDRH](#)

## C·D·R·H Center for Devices and Radiological Health

Search CDRH:  
Powered by Google™

Search



A-Z Index



Send  
Feedback

### Industry Assistance

- Device Advice
- Guidance documents
- Industry Support
- International issues
- Medical device reporting (MDR)
- Obtain market clearance / approval
- Ombudsman
- Standards
- Third party review
- Third party inspection

### Health Topics

### News & Events

FDA Critical Path Initiative - The Critical Path to New Medical Products

[More Information](#)

Possible Barriers to the Availability of Medical Devices Intended to Treat or Diagnose Diseases and Conditions that Affect Children;

[Request for Comments](#)

Announcement of 2<sup>nd</sup> Annual MDUFMA Stakeholder Meeting

Thursday, November 18, 2004

[More Information](#)

FDA Breast Implant Consumer Handbook - 2004 Edition

[More Information](#)

FDA Patient Safety News - June Edition  
[More Information](#)



[View All Recent Items](#)



SUBSCRIBE to  
Daily Updates

### Key topics

- ◆ Heart Health Online
- ◆ Diabetes
- ◆ LASIK
- ◆ CT scanning
- ◆ Breast implants
- ◆ Cell phones
- ◆ Patient Safety Portal
- ◆ Internet sales

### Featured Site



Consumer Information  
on Wireless Phones

### Device Program Areas

Information

# Useful Pages

- **Device Advice**
- **Guidance Documents**
- **Voluntary Standards**
- **Obtain Market Clearance /  
Approval**



## CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

[FDA Home Page](#) | [CDRH Home Page](#) | [Search](#) | [CDRH A-Z Index](#) | [Contact CDRH](#)

**DEVICE ADVICE**  Site Index Help

[Device Advice Home](#) [CDRH Home](#) [Comments](#)

**Device Advice is CDRH's self-service site for medical device and radiation emitting product information. Device Advice is an interactive system obtaining information concerning medical devices.**

Search for  in

Powered by Google

- |  |   |  |
|--|---|--|
| <ul style="list-style-type: none"> <li>▶ Guidance Documents</li> <li>▶ CDRH Databases</li> <li>▶ Code of Federal Regulations</li> <li>▶ Regulatory Manuals</li> <li>▶ <b>International Information</b></li> <li>▶ <b>Consumer Information</b></li> </ul> | <ul style="list-style-type: none"> <li>▶ Overview of Regulations</li> <li>▶ Is Your Product Regulated?</li> <li>▶ Classify Your Device</li> <li>▶ How to Market Your Device</li> <li>▶ Does Your Product Emit Radiation?</li> <li>▶ Registering Your Establishment</li> <li>▶ Listing Your Device</li> <li>▶ Premarket Notification 510(k)</li> <li>▶ 510(k)/GMP Exemption</li> </ul> | <ul style="list-style-type: none"> <li>▶ Investigational Device Exemptions (IDE)</li> <li>▶ Premarket Approval</li> <li>▶ Quality Systems</li> <li>▶ Medical Device Labeling</li> <li>▶ Medical Device Reporting</li> <li>▶ Medical Device Recalls</li> <li>▶ Exporting Medical Devices</li> <li>▶ Medical Device Tracking</li> <li>▶ Postmarket Surveillance Studies</li> </ul> |
|--|---|--|

[CDRH Home Page](#) | [CDRH A-Z Index](#) | [Contact CDRH](#) | [Accessibility](#) | [Disclaimer](#)

# Useful Pages

- Device Advice
- Guidance Documents
- Voluntary Standards
- Obtain Market Clearance / Approval



## Guidance Documents

### Key Topics...

- [Annual Guidance Document Agenda](#)

### About Guidance

- [What is guidance?](#)
- [Abbreviations of CDRH offices producing guidance documents](#)

### Resources

- [Online search of CDRH guidance documents](#)
- [Guidance documents from FDA](#)
- [CDRH Facts on Demand \(FOD\)](#)

Updated June 19, 2003

# Useful Pages

- Device Advice
- Guidance Documents
- Voluntary Standards
- Obtain Market Clearance / Approval



# Standards Program

### Recent Items...

- [Modification to the List of Recognized Standards](#)

### How to use this program

- [Recognition and Use of Consensus Standards](#)
- [FDA Recognized Consensus Standards Database](#)
- [Recommending Standards for CDRH Recognition](#)

### Guidance


- [Frequently Asked Questions on the Recognition of Consensus Standards](#)
- [Recognition and Use of Consensus Standards](#)
- [Use of Standards in Substantial Equivalence Determinations](#)
- [CDRH Standard Operating Procedures for the Identification and Evaluation of Candidate Consensus Standards for Recognition](#)

### Other Resources

- [Federal Register documents](#)
- [Standards Organizations](#)
- [International issues](#)
- International Center Liaison Representative Roster [PDF](#) or [Word](#)
- National Center Liaison Representative Roster [PDF](#) or [Word](#)

# Useful Pages

- Device Advice
- Guidance Documents
- Voluntary Standards
- Obtain Market Clearance /  
Approval



# DEVICE ADVICE



Site Index



Help

[Device Advice Home](#)

[CDRH Home](#)

[Comments](#)

Search for  in  Powered by Google

Please note: as of October 1, 2002, FDA charges fees for review of [Premarket Notification 510\(k\)s](#) and [Premarket Approvals](#)

## Getting To Market With A Medical Device

- [Introduction](#)
- [Three Steps to Obtaining Marketing Clearance from CDRH](#)
- [Classify Your Device](#)
- [Selecting the Appropriate Marketing Application](#)
- [Other Requirements Besides Marketing Clearance](#)
- [In Vitro Diagnostic Devices](#)

### Introduction

One of the most difficult aspects of getting a medical device to market is **KNOWING WHERE TO BEGIN** i.e., what are the steps for marketing and in what order they are to be taken. Essentially, medical devices are subject to the [general controls](#) of the

# Medical Device Amendments

May 28, 1976

# Role of FDA

Establish reasonable  
assurance of the safety and  
effectiveness of medical  
devices marketed  
in the U.S.

# Statutory Basis: *Federal Food, Drug, and Cosmetic Act*

## As amended by:

- **Medical Device Amendments-1976**
  - *Devices Classified*
- **Safe Medical Device Act (SMDA)-1990**
  - *Expanded role*
  - *More detail*
- **FDA Modernization Act-1997**
  - *Redefined (more circumscribed) role*
  - *More interactive with sponsors*
  - *Expanded/earlier access of new technologies to patients*

**Statutory Basis:**  
***Federal Food, Drug, and Cosmetic  
Act (2)***

- **Medical Device User Fee and Modernization Act (MDUFMA) of 2002**
  - *User fees*
  - *Review time goals*

# Medical Device

An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is:

- 1) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man, or 2) intended to affect the structure or any function of the body of man, and

which does not achieve its primary intended purposes through chemical action within or on the body of man and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

Section 201, Food Drug and Cosmetic Act

# Medical Device Approval Process

- Most devices on market prior to May 28, 1976 were “grandfathered”
- Marketing clearance for these devices through 510(k) clearance process--  
Substantially Equivalent
- 510(k)d devices are not approved
- Most radiological products on market using this process

# Routes to Market

- Premarket Submission

  - *501(k)*

- Premarket Approval Application

  - *PMA*

# Grandfathered Devices

- Pre 1976 devices placed into three classes
  - Class I- General controls
  - Class II- Special controls
  - Class III- PMA

# Class I

- Low risk devices
- Safety and effectiveness assured by
  - Good Manufacturing Practices
  - Post-marketing surveillance
  - Registration and listing

# Class II

- Class I controls plus
- “Special controls”
  - Voluntary standards
  - Mandatory standards
  - Guidance
  - Manufacturing inspection

# Class III

- Premarket approval application that establishes Safety and Effectiveness

# 510(k)

- Substantially Equivalent – *New device is compared to a similar device that is on the market.*
- Device need be only as good (or bad) as what was on market in 1976
- 510(k) clearance does not assure effectiveness
- Many devices are exempt from 510(k) submission
- Review time about 90 days

# Medical Device Approval Process

- Devices that sustain life, implants, in class III, or can not be shown substantially equivalent are approved by PMA process
- In a PMA the sponsor must demonstrate that the device is safe and effective for intended use

# PMA'd Devices

- Less than 2% of submissions approved via PMA (similar to NDA)
  - Magnetic Resonance
  - Bone Sonometry
  - Diagnostic ultrasound as an aid in determining breast malignancy
  - CAD devices

# PMA Content

- Indications for use
- Device description
- Laboratory testing
- Preclinical studies
- Clinical studies
- Labeling
- Manufacturing (GMP)

# PMA Process

- Multi discipline review
- May be reviewed by FDA advisory panel
- FDA review time = 180 days
- Data is proprietary

# Routes to Market

- Premarket Submission
  - 501(k)
  - **“Me Too” process**
- Premarket Approval Application
  - PMA
  - ***Determination of Safety and Effectiveness***

# Investigational Use

- Safety and effectiveness studies on devices that are not market cleared
- Needs IRB approval
- Needs informed consent
- FDA involvement depends on “significant risk” vs. “non-significant risk”
- If significant risk = FDA IDE approval needed.
- If not significant risk = Only IRB approval needed

# Investigational Use

- Investigational studies can be multi-phase
- Studies should be well presented
  - Intended indications for use
  - Literature review
  - Scientific basis
  - Safety issues well understood
  - Protocol scientifically sound
  - Reasonable study endpoints

# Pre-investigational Contacts

- FDA/CDRH will meet with you.
- Meetings early in the development/testing stage are desirable
- Meetings are not depended on “significant risk” status
- We work on a “least burdensome” basis

# Summary

- Extensive sources of information are available
- There are multiple pathways to market clearance
- FDA decisions are driven by risk and effectiveness issues
- Contact the appropriate FDA/CDRH component early in the process

# FY2004 Submission Fees

	Fee Rates	
PMA	Full	Sm. Bus.
Full Fees	\$206,811	\$78,588
180-Day Supps	\$ 44,464	\$16,896
Real-Time Supps.	\$ 14,890	\$5,658
510(k)'s	\$ 3,480	\$2,784

# Fee Exemptions and Waivers

- First time PMA application from a small business – waiver
- Any device intended to be used solely for pediatric use – exempt from fees
- State or Federal government applications – exempt from fees (ex for comm. dist.)
- Small Business = Ann gross revenue  $\leq$  \$30M

# What the “Critical Path” Is

- A serious attempt to bring attention & focus to the need for more scientific effort and publicly-available information on *evaluative tools*
- **Evaluative tools:** The techniques & methodologies needed to evaluate the safety, efficacy & quality of medical devices as they move down the path

# Contact

- **Web Address:**

<http://www.fda.gov/oc/initiatives/criticalpath/>

- **Open Docket:**

<http://www.fda.gov/dockets/ecomments>

**Docket # 2004N-0181**

- **CDRH webpage (under news and events) provides links to the critical path white paper and docket:**

<http://www.fda.gov/cdrh/>